Multiple Sclerosis and the launch of Ocrevus



Multiple Sclerosis and the launch of Ocrevus

Slides in the pack:

  1. Multiple sclerosis (MS), the disease area
  2. MS affects Caucasians more than people of other races
  3. Greater prevalence of MS in higher northern and southern latitudes – with prevalence data
  4. Treatments for MS
  5. In March 2017, the FDA approved Ocrevus, the first drug to treat severe MS
  6. Phase III trial results for Ocrevus in relapsing-remitting MS
  7. Game-changing results with Ocrevus compensated for its severe side effects in the opinion of payers
  8. Recently launched or in-pipeline drugs that may emerge as threats to Ocrevus
Reviews (0)


There are no reviews yet.

Be the first to review “Multiple Sclerosis and the launch of Ocrevus”

Your email address will not be published. Required fields are marked *